One-Year Follow-Up Results of MIS-C Patients with Coronary Artery Involvement: A Multi-center Study


BAYKAN A., KUM Y. E., Yilmazer M. M., Varan C., Yakut K., SERT A., ...Daha Fazla

PEDIATRIC CARDIOLOGY, cilt.45, sa.2, ss.282-291, 2024 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 45 Sayı: 2
  • Basım Tarihi: 2024
  • Doi Numarası: 10.1007/s00246-023-03364-x
  • Dergi Adı: PEDIATRIC CARDIOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS
  • Sayfa Sayıları: ss.282-291
  • Anahtar Kelimeler: Aneurysm, Coronary artery, COVID-19, Dilatation, Multisystem inflammatory syndrome in children
  • Erciyes Üniversitesi Adresli: Evet

Özet

Multisystem inflammatory syndrome (MIS-C) in children is a rare complication of SARS-CoV-2 infection. Knowing the course of the affected or unaffected coronary arteries in the patients under follow-up is important in terms of defining the long-term prognosis of the disease and determining the follow-up plan. This is a multicenter and retrospective study. The data were obtained from nine different centers. Between May 2020 and August 2022, 68 of 790 patients had coronary artery involvement. One-year echocardiographic data of 67 of 789 MIS-C patients with coronary artery involvement were analyzed. Existing pathologies of the coronary arteries were grouped as increased echogenicity, dilatation and aneurysm according to Z scores, and their changes over a 1-year period were determined. The data of all three groups are defined as frequency. SPSS Statistics version 22 was used to evaluate the data. In our study, aneurysm was observed in 16.4%, dilatation in 68.7% and increased echogenicity in 13.4% of the patients. All of the patients with involvement in the form of increased echogenicity recovered without sequelae by the end of the first month. No progression to aneurysm was observed in any of the patients with dilatation. No new-onset involvement was observed in patients with previously healthy coronary arteries during the convalescent period. In addition, from the sixth month follow-up period, there was no worsening in the amount of dilatation in any of the patients. At least 94% of the patients who completed the 12th month control period returned to normal.